The Fast-Track Protocol

The Scenario Is Just the Vehicle

An executive bypasses the contract system to sign a trial-site agreement on time, and a buried clause detonates months later.

What This Lab Is Really About

Whether a company that trained everyone on its compliance tool has actually changed behavior, or just bought a dashboard that hides every shortcut it doesn’t capture.

The real discussion is not about a single contract or a single executive. It is about a culture that crowns whoever hits the milestone, a side door no one closed, and a compliance metric that reports 100% adoption while the contracts keeping the company afloat never touch the system.

This Is Not a Debate About the Shortcut

The Lab assumes the shortcut already happened. It never relitigates whether the VP should have signed.

Everyone in the room already knows signing an unvetted contract over email was wrong. If the lab argues that, it becomes a blame session, and no one is tested. The pressure lives in what they confront now: a contract that isn’t in the system, liability they can’t locate, a licensing deal suddenly at risk — and the harder truth that the company built a control, trained everyone on it, watched a green dashboard, and was blind the whole time. The tool was never the problem. The behavior around it was.

Inject 1 · The Hero

The milestone was hit. The site is onboarded, enrollment is on track, the stock ticked up, and the VP of Clinical Operations is praised for getting it done when the system would have cost three days. The room’s first instinct: this is a win.

Inject 2 · The Event

Four months in, a serious adverse event and a patient-data breach occur at that site. Regulators freeze it and threaten an audit. The room moves to assess liability and assumes the contract protects them — “pull it up, check indemnification and the data clauses.” This is the trap closing. The room is meant to assume the paperwork is fine.

Inject 3 · The Shock Drop (the detonator)

The contract isn’t in the CLM. The VP digs the signed PDF out of an inbox, and it goes up on the projector. By signing the site’s “non-negotiable” document, the company accepted two buried terms: full liability — standard CRO indemnification stripped away — and IP exposure — the site co-owns any “unexpected discoveries” or secondary data generated in the trial.

Everything inverts. The contaminated data and stripped indemnification put the company on the hook for the breach, and the co-ownership clause threatens the strategic licensing deal, much of which rests on. And the sting: the compliance dashboard read 100% adoption the entire time — it only ever tracked the contracts that followed the rule.

“We’d never let someone bypass Legal and bind the company on a tablet over email.”

No one in the room would ever approve that — and that’s exactly why this Lab works. Nobody decides to strip the company of its indemnification or give away its IP. The Friday-5:00 enrollment target, the three-day legal queue with no fast lane, a counterparty that refuses your system, and a culture that crowns whoever hits the milestone decide it for them — one reasonable-sounding shortcut at a time. And the dashboard that shows 100% adoption is hiding the exact contracts that didn’t go through. Good people, good intentions, structural outcome.

VP of Clinical Operations — owns the enrollment milestone and signed to save the launch. “The system is too slow for the real world.” Not the villain — this is the behavior the company rewarded.

Chief Medical Officer / Head of R&D — the Phase 3 data is now entangled in a legal and IP dispute, and the strategic licensing deal is suddenly at risk. Owns the science and the pipeline.

CCO / General Counsel — just launched mandatory CLM training; the control was bypassed anyway, on a public company under SEC and FDA scrutiny. Staring at a contract that doesn’t exist in the system, and a side door that no one closed.

CFO — weighs the liability for the breach, the audit, and a licensing deal that may now be dead against the investor confidence the milestone was supposed to protect.

CEO — owns whether the culture rewards the hero who breaks the rules, and what changes now. Makes the call on whether speed or control wins the next time the clock runs out.

Training ≠ Behavior

A how-to course on the tool does nothing if the culture still rewards the hero who breaks the rules to hit a date. What actually happens to someone who misses a milestone because they followed the process?

The E-Signature Side Door

We bought the CLM but left corporate e-signature credentials wide open. Who can still legally bind the company to a catastrophic clause over email right now — and what would close that door?

The Dashboard Delusion

Our 100%-adoption metric measures only the contracts that followed the rule. What is the metric that would have shown us the shadow contracts — the ones we never see?

The Missing Fast Lane

When a counterparty refuses our system and a real deadline is bearing down, who can grant an exception, and how quickly — or does the absence of a fast lane guarantee a workaround?

0–10 min — Frame. Set the rule of the room: the shortcut already happened. We are deciding what we do now and what we change so the dashboard stops lying.

10–30 min — Inject 1. The hero and the milestone hit. The “this is a win” instinct surfaces.

30–50 min — Inject 2. The adverse event. Let the room move to assess liability and assume the contract protects them.

50–70 min — Inject 3. The shock drop: the missing contract, the stripped indemnification, the IP co-ownership, the dashboard that lied.

70–90 min — Reframe & commit. The surfacing questions, then the decisions the room carries out — the side door, the fast lane, the real metric, and the culture.

Facilitator’s guide — full run-of-show, timing, the rule of the room, and how to hold the line against the blame-session drift.

The three inject cards — sequenced for timed reveal, with Inject 3 (the shock drop) held as the detonator.

Role briefs — one per seat (Clinical Ops, CMO/R&D, CCO/GC, CFO, CEO), each with the pressure that seat carries.

Reframe & surfacing-question set — the “we’d never bypass Legal” turn and the four questions to leave open.

Legal-context primer — a plain-language, counsel-hedged page on CRO/site indemnification, cross-border clinical-data privacy, IP and secondary-discovery ownership, and why an e-signature binds the company even when the dashboard never sees it.

Commitments template — who can bind the company and how the e-signature side door gets closed, the exception/fast-lane path for real deadlines, and the metric that would surface shadow contracts.

Debrief one-pager — the takeaways and the homework, sized for a follow-up email to the room.

Part of the Executive Decision Lab™ line. Each Lab puts a leadership team inside a high-pressure decision where the right answer is obvious in principle and hard in practice. Explore the full line of Executive Decision Labs.